Table 5.

Response rates.

Variable, n (%)	All (N = 91)	Treatment naïve		Relapsed or ≥second line
		Bendamustine monotherapy (n = 10)	Bendamustine + rituximab combination therapy (n = 6)	Bendamustine monotherapy (n = 20)	Bendamustine + rituximab combination therapy (n = 55)
Overall response rate* [95% CI]	53 (58.2) [47.4–68.5]	5 (50.0) [18.7–81.3]	4 (66.7) [22.3–95.6]	9 (45.0) [23.0–68.4]	35 (63.6) [49.5–76.2]
Complete response [95% CI]	13 (14.3) [7.8–23.2]	1 (10.0) [0.25–44.5]	2 (33.3) [4.3–77.7]	4 (20.0) [5.7–43.6]	6 (10.9) [4.1–22.2]
Partial response [95% CI]	39 (42.9) [32.5–53.6]	4 (40.0) [12.1–73.7]	2 (33.3) [4.3–77.7]	5 (25.0) [8.6–49.1]	28 (50.9) [37.0–64.6]
Nodular partial response	1 (1.1)	0	0	0	1 (1.8)
Stable disease	14 (15.4)	2 (20.0)	2 (33.3)	5 (25.0)	5 (9.1)
Progressive disease	19 (20.9)	1 (10.0)	0	5 (25.0)	13 (23.6)
Missing	5 (5.5)	2 (20.0)	0	1 (5.0)	2 (3.6)

CI, confidence interval.

^*Overall response rate = complete response + partial response + nodular partial response.